NCT06716138View on ClinicalTrials.gov

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

March 6, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

March 30, 2029

Conditions
Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Interventions
DRUG

ANS03

ANS03 is a rationally next generation TKI targeting both ROS1 and NTRK developed by Shenzhen Avistone Biotechnology (the sponsor).

Trial Locations (6)

10022

NOT_YET_RECRUITING

Research Site, New York

Unknown

NOT_YET_RECRUITING

Research Site, Fuzhou

NOT_YET_RECRUITING

Research Site, Guangzhou

RECRUITING

Research Site, Shanghai

NOT_YET_RECRUITING

Research Site, Shanghai

NOT_YET_RECRUITING

Research Site, Chengdu

All Listed Sponsors
lead

Avistone Biotechnology Co., Ltd.

INDUSTRY